Physician

Jorge Arturo Rios-Perez, M.D.

According to 2025 Medicare claims, Jorge Rios-Perez, M.D. (NPI: 1710143847) practices hematology/oncology in the Columbus, OH market, with the plurality of this provider's patient population coming from Franklin, OH. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 43219-1530. Rios-Perez is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Rios-Perez's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 225 traditional Medicare patients, billed 51,439 HCPCS/CPT codes, and received $1,039,860 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 562 prescription claims across 144 beneficiaries totaling $2,434,986 in drug costs, led by Revlimid (Lenalidomide). 2016 DME data shows 12 claims. Open Payments data shows 21 records totaling $95,030. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $23,551 to $1,039,860. Similarly, Part D prescription costs have moved sharply higher in recent years, from $187,365 to $2,434,986. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	117	404	$23,551
2016	107	1,267	$36,577
2017	288	38,953	$414,043
2018	280	57,339	$733,202
2019	276	53,311	$837,383
2020	264	41,994	$1,078,704
2021	250	59,350	$1,310,316
2022	280	69,913	$1,652,938
2023	299	54,121	$1,335,042
2024	225	51,439	$1,039,860

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	60	384	$187,365
2016	52	370	$510,023
2017	88	348	$505,242
2018	90	520	$742,396
2019	96	512	$1,240,816
2020	88	519	$1,143,718
2021	119	591	$1,070,356
2022	156	703	$1,744,365
2023	160	617	$1,729,207
2024	144	562	$2,434,986

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$771
2016	N/R	12	$627
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	121	286	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	126	240	$62
36415	Insertion of needle into vein for collection of blood sample	140	491	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	150	529	$8
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	42	8,102	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	43	1,134	$579,589
Pomalyst	Pomalidomide	14	392	$314,539
Tagrisso	Osimertinib Mesylate	19	570	$313,719
Imbruvica	Ibrutinib	14	400	$208,559
Lenalidomide	Lenalidomide	11	308	$174,440

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$344	SpringWorks Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$94,686	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jorge Arturo Rios-Perez, M.D.?

Tedicare shows public-source Medicare data for Jorge Arturo Rios-Perez, M.D. (NPI 1710143847), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jorge Arturo Rios-Perez, M.D. have ACO affiliation data?

Jorge Arturo Rios-Perez, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Jorge Arturo Rios-Perez, M.D.?

Jorge Arturo Rios-Perez, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Jorge Arturo Rios-Perez, M.D. have Open Payments data?

Jorge Arturo Rios-Perez, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.